VivoSeq
Hematology

Sickle Cell Anemia

6

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Sickle Cell Anemia is an early-stage landscape with 6 programs across 4 companies. The most active players are Roche, Genzyme, a Sanofi Company, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

PreclinicalG

Genzyme, a Sanofi Company

1 program

PreclinicalSanofi logo

Sanofi

1 program

PreclinicalAlnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical6

CD45RA Depleted Leukocytes

Paul Szabolcs

Hydroxyurea

Theravia

Rituximab

Roche

Alemtuzumab

Genzyme, a Sanofi Company

Fludarabine

Sanofi

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

60%

Small molecule

3 of 5 classified programs — the dominant modality here.

40%ALL OTHERSMonoclonal antibody240%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 100% of 7 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Active, not recruiting1 · 50%

Clinical Trials

Trial Activity

T-Cell Depleted, Alternative Donor Transplant in Pediatric and Adult Patients With Severe Sickle Cell Disease (SCD) and Other Transfusion-Dependent Anemias
Recruiting·—·Preclinical·NCT03653338·5 enrolled
Observational Study Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease
Active, not recruiting·National Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT05675436·6 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)